Equities Analysts Set Expectations for EPRX FY2025 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Equities researchers at Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for shares of Eupraxia Pharmaceuticals in a report issued on Thursday, December 11th. Lifesci Capital analyst S. Slutsky expects that the company will post earnings per share of ($0.72) for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. Lifesci Capital also issued estimates for Eupraxia Pharmaceuticals’ Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.75) EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04.

Several other brokerages have also recently weighed in on EPRX. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Eupraxia Pharmaceuticals in a report on Wednesday, August 20th. Leede Financial upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eupraxia Pharmaceuticals has an average rating of “Buy” and an average target price of $11.67.

Eupraxia Pharmaceuticals Stock Performance

Shares of Eupraxia Pharmaceuticals stock opened at $6.25 on Monday. The firm has a 50-day moving average of $5.99 and a 200-day moving average of $5.48. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $7.19. The stock has a market cap of $224.75 million, a PE ratio of -7.18 and a beta of 1.38.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Quadrature Capital Ltd bought a new stake in Eupraxia Pharmaceuticals during the second quarter worth $61,000. TCI Wealth Advisors Inc. bought a new position in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at $65,000. Integrated Wealth Concepts LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth $71,000. Bank of America Corp DE lifted its position in shares of Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after buying an additional 10,059 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Eupraxia Pharmaceuticals by 593.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after buying an additional 16,017 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.